Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06651866 | Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients | recruiting | Phase 1 | 18 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06737523 | Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML | recruiting | Phase 1 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 24, 2025 |
| clinicaltrials |
| NCT06088888 | TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia | recruiting | Phase 1 | 90 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05066412 | Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC | recruiting | Phase 1 | 12 | University Hospital, GenevaOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06822868 | A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma(CT1190B) | recruiting | Phase 1 | 24 | Kai HuOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06642792 | A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 280 | AkesoINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06464861 | Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma(CD19-CARNK/T) | recruiting | Phase 1 | 52 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05341557 | A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma | recruiting | Phase 1 | 110 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT04807881 | Phase Ib Clinical Study of Keynatinib | recruiting | Phase 1 | 75 | Medolution Ltd.INDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
| NCT05601726 | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients(ODYSSEY) | recruiting | Phase 1 / Phase 2 | 36 | Advanced BioDesignINDUSTRY | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06225310 | A Trial of Selinexor, Ruxolitinib and Methylprednisolone(KPT-IST-391) | recruiting | Phase 1 | 30 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT05488548 | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 75 | Epigenetix, Inc.INDUSTRY | 1 | Jan 14, 2025 | clinicaltrials |
| NCT05054257 | CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma(UHKT-CAR19-01) | recruiting | Phase 1 | 10 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06758713 | Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies | recruiting | Phase 1 | 60 | The Third Affiliated Hospital of Southern Medical UniversityOTHER_GOV | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06759181 | Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06734871 | A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma(CT1190B) | recruiting | Phase 1 | 24 | Aibin Liang，MD，Ph.D.OTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06752785 | CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. | recruiting | Phase 1 | 10 | Guangzhou Women and Children's Medical CenterOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05690581 | Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies | recruiting | Phase 1 | 146 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746519 | BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 135 | Chen SuningOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05967416 | Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | recruiting | Phase 1 | 24 | SIRPant Immunotherapeutics, Inc.INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06332430 | Intratumoral CAN2109 in Subjects With Solid Tumors | recruiting | Phase 1 | 27 | Canwell Biotech LimitedINDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06739265 | Golidocitinib Plus CHOP in Newly Diagnosed PTCL | recruiting | Phase 1 / Phase 2 | 68 | Peking Union Medical College HospitalOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06731699 | A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS | recruiting | Phase 1 | 72 | Chengdu FenDi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06735495 | CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors | recruiting | Phase 1 / Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05934513 | A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | recruiting | Phase 1 / Phase 2 | 95 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06083207 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 116 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Dec 13, 2024 | clinicaltrials |
| NCT06725524 | A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 186 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06101381 | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma(CARTHEDRALL) | recruiting | Phase 1 / Phase 2 | 81 | University of Sao PauloOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05476770 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | recruiting | Phase 1 | 54 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Dec 6, 2024 | clinicaltrials |
| NCT06700395 | A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma | recruiting | Phase 1 | 136 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06720324 | CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors | recruiting | Phase 1 / Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT05806099 | A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL | recruiting | Phase 1 / Phase 2 | 132 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06034275 | Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies | recruiting | Phase 1 | 36 | Vincerx Pharma, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT05156203 | Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors | recruiting | Phase 1 | 30 | Taivex Therapeutics CorporationINDUSTRY | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06420063 | Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML(BAH244) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06420076 | Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells(BAH246) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06644118 | A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) | recruiting | Phase 1 | 58 | Zhejiang UniversityOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT05503134 | Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML(KARMA) | recruiting | Phase 1 / Phase 2 | 20 | Nationwide Children's HospitalOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06176027 | Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas | recruiting | Phase 1 / Phase 2 | 52 | Navy General Hospital, BeijingOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT05312801 | Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma | recruiting | Phase 1 | 20 | Luminary TherapeuticsINDUSTRY | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05546723 | LMY-920 for Treatment of Relapsed or Refractory Myeloma(LMY-920-002) | recruiting | Phase 1 | 30 | Luminary TherapeuticsINDUSTRY | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06644443 | BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04275518 | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. | recruiting | Phase 1 | 102 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05299424 | A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 48 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06635330 | Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL | recruiting | Phase 1 / Phase 2 | 5 | Kara Yakhteh Tajhiz Azma CompanyNETWORK | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06615193 | A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor | recruiting | Phase 1 | 111 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06592170 | Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)(MZL-001) | recruiting | Phase 1 / Phase 2 | 35 | The First Hospital of Jilin UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06593145 | CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms(CARLA) | recruiting | Phase 1 | 6 | FamiCordTxINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06585345 | Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia | recruiting | Phase 1 / Phase 2 | 200 | The General Hospital of Western Theater CommandOTHER | 1 | Sep 5, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 24, 2025source: clinicaltrials